VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial.
Moreau P et al. Blood. 2016 Mar 21. pii: blood-2016-01-693580. [Epub ahead of print].
Intravenous (IV) bortezomib infusion after non-response to subcutaneous bortezomib administration can induce transitory responses in multiple myeloma patients: are some patients more sensitive to IV bortezomib?
Gozzetti A et al. Br J Haematol. 2016 Mar 11. doi: 10.1111/bjh.14032. [Epub ahead of print].
A novel hematopoietic progenitor cell mobilization regimen, utilizing bortezomib and filgrastim, for patients undergoing autologous transplant.
Abhyankar S et al. J Clin Apher. 2016 Mar 4. doi: 10.1002/jca.21449. [Epub ahead of print].
Efficacious and save use of biosimilar filgrastim for hematopoietic progenitor cell chemo-mobilization with vinorelbine in multiple myeloma patients.
Maul JT et al. J Clin Apher. 2016 Mar 22. doi: 10.1002/jca.21459. [Epub ahead of print].
Single versus tandem high-dose melphalan followed by autologous blood stem cell transplantation in multiple myeloma: long-term results from the phase III GMMG-HD2 trial.
Mai EK et al. Br J Haematol. 2016 Mar 17. doi: 10.1111/bjh.13994. [Epub ahead of print].
Tandem autologous versus autologous/allogeneic transplantation for multiple myeloma: propensity score analysis.
Kawamura K et al. Leuk Lymphoma. 2016 Mar 9:1-7. [Epub ahead of print].
Lenalidomide with low- or intermediate-dose dexamethasone in patients with relapsed or refractory myeloma.
Zagouri F et al. Leuk Lymphoma. 2016 Feb 25:1-5. [Epub ahead of print].
Randomized multicenter phase II study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma.
Baz RC et al. Blood. 2016 Mar 1. pii: blood-2015-11-682518. [Epub ahead of print].